Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Consensus Target Price from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been assigned an average recommendation of “Hold” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $27.22.

Several brokerages recently commented on PCRX. HC Wainwright lifted their target price on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Needham & Company LLC lifted their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Barclays lifted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its position in shares of Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after acquiring an additional 2,799,434 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $20,266,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $8,558,000. Balyasny Asset Management L.P. acquired a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $8,180,000. Finally, Nuveen Asset Management LLC boosted its position in shares of Pacira BioSciences by 109.9% during the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company’s stock valued at $11,792,000 after acquiring an additional 327,754 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Stock Up 0.8 %

Pacira BioSciences stock opened at $22.87 on Monday. The company has a market capitalization of $1.06 billion, a P/E ratio of -11.27 and a beta of 0.86. The firm’s fifty day simple moving average is $23.96 and its 200-day simple moving average is $19.31. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.